Currently Viewing:
Newsroom
Currently Reading
Pfizer Announces Phase 3 Trial for Atopic Dermatitis Treatment
December 15, 2017 – Samantha DiGrande
Majority of Women With Breast Cancer Surgery Did Not Feel Fully Informed of Treatment Options
December 15, 2017 – Jaime Rosenberg
AJMC® in the Press, December 15, 2017
December 15, 2017 – AJMC Staff
What We're Reading: Medicare Lab Testing; CHIP Deadline; AMA Expands Diabetes Efforts
December 15, 2017 – AJMC Staff
5 Key Takeaways From ASH 2017
December 15, 2017 – Surabhi Dangi-Garimella, PhD
This Week in Managed Care: December 15, 2017
December 15, 2017
What We're Reading: Medical Device Tax; Marijuana and Vaping; Birth Control Without Prescriptions
December 14, 2017 – AJMC Staff
Study Finds Breathing Retraining Associated With Quality of Life Improvement for Patients With Asthma
December 14, 2017 – Laura Joszt
Rain and Pain Not Related, Harvard Researchers Say
December 13, 2017 – Allison Inserro

Following Pembrolizumab, Nivolumab Trials in Multiple Myeloma Paused

Surabhi Dangi-Garimella, PhD
Bristol-Myers Squibb announced that the FDA has placed a clinical hold on 3 combination trials evaluating its programmed death-1 inhibitor nivolumab (Opdivo) in patients with relapsed/refractory multiple myeloma.
In a press release late Wednesday, Bristol-Myers Squibb (BMS) announced that the FDA has placed a clinical hold on 3 combination trials evaluating its programmed death-1 (PD-1) inhibitor nivolumab (Opdivo) in patients with relapsed/refractory multiple myeloma.

The hold, according to the company, is in reaction to trials evaluating another anti–PD-1 agent, pembrolizumab (Keytruda), that were placed on hold following patient deaths. In July, Merck, which has developed pembrolizumab, announced that the FDA’s decision applied to KEYNOTE-183, KEYNOTE-185, and KEYNOTE-023; the trials were evaluating the drug in combination with various other agents in either treatment-naïve or relapsed/refractory patients with multiple myeloma.

Earlier this week, the FDA followed up with a more detailed analysis of what resulted in the deaths—higher rate of grade 3 to 5 toxicities, higher rate of serious adverse events, and some non-cancer causes of death, including cardiac events and intestinal ischemia.

Nivolumab trials that have been placed on partial clinical hold include:
  • CheckMate-602: A phase 3 trial of combinations of nivolumab, elotuzumab, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma
  • CheckMate-039: A phase 1 study to establish the tolerability of nivolumab and the combination of nivolumab and daratumumab, with or without IMiD (pomalidomide and dexamethasone), in subjects with relapsed or refractory multiple myeloma
  • CA204142: A phase 2 study of elotuzumab in combination with pomalidomide and low-dose dexamethasone, and in combination with nivolumab, in patients with multiple myeloma relapsed or refractory to prior treatment with lenalidomide
Other nivolumab studies for indications other than multiple myeloma will continue as planned, according to the BMS release.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!